Background
Methods
Patients
Examinations
Statistical analysis
Results
Baseline demographic and clinical characteristics
TBP (223 cases) | Non-TBP (42 cases) | P-value | |
---|---|---|---|
Age, mean (SD) [range], years | 41.3 (17.6) [15–83] | 56.4 (13.9) [25–81] | < 0.001 |
Male gender, No. (%) | 138 (61.9) | 25 (59.5) | 0.713 |
BMIa, median (range) | 19.5 (15–27) | 19.3 (14–29) | 0.066 |
Fever (%) | 129 (57.9) | 22(52.4) | 0.512 |
Course of disease [range], weeks1 | 5.2 [1–52] | 2.1 [1–208] | < 0.001 |
Diabetes mellitus (%) | 22 (9.9) | 4 (9.5) | 0.946 |
History of anti-TB treatment | 19 (8.5%) | 1 (2.4%) | 0.167 |
ADA (U/liter) > 25 | 201 (90.13%) | 10 (23.8%) | < 0.001 |
LPb > 50% | 118 (52.9%) | 16 (38.1%) | 0.078 |
Without intrapulmonary lesions | 5 (2.2%) | 12 (28.6%) | < 0.001 |
T-SPOT.TB on PBMCsc | 208 (93.3%) | 5 (11.9%) | < 0.001 |
Results of LAMP, Xpert MTB/RIF and SAT-TB assay
Method | Diagnostic rate | |
---|---|---|
TP (223 cases) | Non-TBP (42 cases) | |
PE smear | 32 (14.3%) | 4 (9.5%) |
LAMP positive | 59 (26.5%) | 1 (2.4%) |
Xpert positive | 61 (27.4%) | 0 |
SAT-TB positive | 72 (32.3%) | 0 |
Method | Sensitivity | Specificity | PPV | NPV | Accuracy |
---|---|---|---|---|---|
PE smear | 14.3% | 90.9% | 88.9% | 16.6% | 26.4% |
LAMP | 26.5% | 97.6% | 98.3% | 20.0% | 37.7% |
Xpert | 27.4% | 100% | 100% | 20.6% | 38.0% |
SAT-TB | 32.3% | 100% | 100% | 21.8% | 43.0% |
Method | PE smear | Xpert | LAMP | SAT-TB | P-value |
---|---|---|---|---|---|
Low-ADA(64) | 7 (10.94%) | 13 (20.31%) | 16 (25.00%) | 17 (26.56%) | 0.123 |
Medium-ADA(117) | 17 (14.53%) | 32 (27.35%) | 25 (21.37%) | 34 (29.06%) | 0.035 |
High-ADA(42) | 8 (19.05%) | 16 (38.10%) | 18 (42.86%) | 21 (50.00%) | 0.024 |
Total | 32 | 61 | 59 | 72 |
Establishment of ROC curve
Results of DST to first-line drugs
Susceptibility test | Primary TBP (N = 204) | Retreatment TBP (N = 19) | Total (N = 223) |
---|---|---|---|
MDR | 10 (4.9%) | 10 (52.6%) | 20 (9.0%) |
Rifampicin | 1 (0.5%) | 0 | 1 (0.4%) |
PDR | 9 (4.4%) | 1 (5.3%) | 10 (4.5%) |
Isoniazid | 6 (2.9%) | 3 (15.8%) | 9 (4.0%) |
Ethambutol | 1 (0.5%) | 0 | 1 (0.4%) |
Streptomycin | 59 (26.5%) | 1 (2.4%) | 60 (26.9%) |